NHS Galleri Trial Cuts Stage 4 Cancer Diagnoses by Over 20% in 142,000-Volunteer Study
Updated
Updated · News - · May 29
NHS Galleri Trial Cuts Stage 4 Cancer Diagnoses by Over 20% in 142,000-Volunteer Study
10 articles · Updated · News - · May 29
More than 142,000 volunteers aged 50–77 in England showed at least 20% fewer stage 4 cancer diagnoses in the second and third screening rounds when given the Galleri blood test.
The multi-cancer test was added to existing NHS screening and looks for a shared cancer signal in blood samples taken three times over two years.
The trial still missed its main goal: it found no overall reduction in combined late-stage cancers, defined as stage 3 and stage 4 diagnoses together over three years.
Researchers said the stage 4 decline strengthened by the third year and could be clinically meaningful because cancers caught before stage 4 are more likely to be treated with curative intent.
Further analysis will continue over coming months and years, with investigators calling the study the first and largest trial of its kind.
This blood test finds more cancers, but could a flood of false alarms overwhelm our health system?
A new cancer test missed its main goal but cut deadly cases. Is this a true medical breakthrough?
NHS-Galleri Trial Results: Missed Primary Target, 4x Early Cancer Detection, and the Debate Over MCED Test Adoption
Overview
The NHS-Galleri trial's initial findings showed a mixed picture: while the study failed to meet its primary goal and drew criticism in the UK, it also revealed promising secondary signals. News headlines called the test a failure, and some experts described the trial as a flop, leading to concerns for Grail, the company behind the Galleri test. However, the trial also showed that the test could help diagnose some cancers earlier and potentially prevent late-stage diagnoses. These results suggest that, despite setbacks, the Galleri test may still offer benefits for early cancer detection.